Evotec Deal History & Licensing Activity
Evotec is a biotech headquartered in Germany. Over the past three years, Evotec has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 3 active clinical trials, primarily in Immunology.
Deals (12mo)
2
Active Trials
3
Top Modality
Small Molecules
Focus Area
Immunology
Evotec Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Evotec in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Odyssey Therapeutics | Small Molecules | Discovery | collaboration | Aug 6, 2026 |
| Undisclosed | Bristol Myers Squibb | Other | Discovery | collaboration | Oct 27, 2025 |
Evotec Pipeline Focus
Therapeutic areas and modalities where Evotec is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Evotec Clinical Pipeline
Evotec has 3 active clinical trials across 2 development phases.
1
Unknown
2
Phase 1
See How Your Asset Matches Evotec's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Evotec Licensing & Deal Activity
Evotec is a biotech company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Evotec ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Evotec include Immunology (2 deals and trials), Neurology (2 deals and trials), Rare Disease (1 deal and trial), and Infectious (1 deal and trial). In terms of modality, Evotec has shown particular interest in small molecules, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Evotec and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Evotec's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.